Loading...
XNAS
RPRX
Market cap13bUSD
Mar 31, Last price  
31.13USD
1D
-0.77%
1Q
22.03%
IPO
-35.96%
Name

Royalty Pharma PLC

Chart & Performance

D1W1MN
No data to show
P/E
15.70
P/S
5.96
EPS
1.98
Div Yield, %
2.02%
Shrs. gr., 5y
10.13%
Rev. gr., 5y
4.53%
Revenues
2.26b
-3.85%
1,652,420,0001,877,410,0001,597,930,0001,794,894,0001,814,254,0002,122,000,0002,289,463,0002,237,215,0002,354,554,0002,264,000,000
Net income
859m
-24.31%
581,426,000565,907,0001,210,025,0001,377,729,0002,348,535,000495,198,000478,754,00042,832,0001,134,834,000859,000,000
CFO
2.77b
-7.32%
1,418,313,0001,618,317,0001,667,239,0002,034,629,0002,017,536,0002,143,980,0002,987,802,0002,768,986,000
Dividend
Aug 16, 20240.21 USD/sh
Earnings
May 07, 2025

Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
URL
https://www.royaltypharma.com
IPO date
Jun 16, 2020
Employees
Domiciled in
US
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,264,000
-3.85%
2,354,554
5.24%
2,237,215
-2.28%
Cost of revenue
239,000
862,404
410,079
Unusual Expense (Income)
NOPBT
2,025,000
1,492,150
1,827,136
NOPBT Margin
89.44%
63.37%
81.67%
Operating Taxes
472,000
187,232
Tax Rate
23.31%
10.25%
NOPAT
1,553,000
1,492,150
1,639,904
Net income
859,000
-24.31%
1,134,834
2,549.50%
42,832
-91.05%
Dividends
(376,465)
(358,327)
(333,322)
Dividend yield
2.49%
2.12%
1.93%
Proceeds from repurchase of equity
(229,651)
(304,759)
BB yield
1.52%
1.80%
Debt
Debt current
997,773
997,512
Long-term debt
6,614,653
6,135,285
6,118,810
Deferred revenue
Other long-term liabilities
12,080
900
2,500
Net debt
6,438,240
4,627,494
(9,540,398)
Cash flow
Cash from operating activities
2,768,986
2,987,802
2,143,980
CAPEX
2,041,152
Cash from investing activities
(2,678,115)
(2,072,789)
(1,029,421)
Cash from financing activities
361,145
(2,148,754)
(944,856)
FCF
1,584,480
874,644
1,639,904
Balance
Cash
987,226
495,310
2,427,791
Long term investments
186,960
1,012,481
14,228,929
Excess cash
1,060,986
1,390,063
16,544,859
Stockholders' equity
2,921,509
6,075,483
5,862,082
Invested Capital
16,905,886
14,830,411
10,782,113
ROIC
9.79%
11.65%
15.34%
ROCE
11.27%
9.20%
10.98%
EV
Common stock shares outstanding
592,726
602,900
437,972
Price
25.51
-9.18%
28.09
-28.92%
39.52
-0.83%
Market cap
15,120,440
-10.72%
16,935,461
-2.16%
17,308,653
4.71%
EV
21,634,491
25,120,747
11,665,478
EBITDA
2,025,000
1,512,649
1,832,806
EV/EBITDA
10.68
16.61
6.36
Interest
226,000
187,187
187,961
Interest/NOPBT
11.16%
12.54%
10.29%